TerrAscend's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 20.17.
TerrAscend's Days Inventory for the
three
months ended in Mar. 2026 was 103.02.
TerrAscend's Days Payable for the
three
months ended in Mar. 2026 was 116.92.
Therefore, TerrAscend's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 6.27.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
TerrAscend Cash Conversion Cycle Related Terms
TerrAscend Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for TerrAscend's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:TED vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where TerrAscend's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
TerrAscend's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (STU:TED) has a Cash Conversion Cycle of 6.27 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on TerrAscend and its competitors.
Is TerrAscend's Cash Conversion Cycle too high?
TerrAscend's current Cash Conversion Cycle is 6.27. The Drug Manufacturers industry median Cash Conversion Cycle is 145.87. TerrAscend's value of 6.27 is 95.7% below this industry median. Overall, TerrAscend has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's Cash Conversion Cycle compare to ZTS and UTHR?
TerrAscend's Cash Conversion Cycle of 6.27 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.87. TerrAscend's value of 6.27 is 95.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.87, based on 948 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current Cash Conversion Cycle of 6.27 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on TerrAscend and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current Cash Conversion Cycle is 6.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (STU:TED) is currently considered Possible Value Trap. The stock's GF Value™ is €0.85, compared to a current price of €0.58 — trading 31.5% below its estimated fair value. The current Cash Conversion Cycle is 6.27 and 95.7% below the Drug Manufacturers industry median of 145.87. TerrAscend's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For TerrAscend (STU:TED), the current Cash Conversion Cycle is 6.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (STU:TED) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of €0.58 is trading 31.5% below its estimated GF Value™ of €0.85.
GuruFocus considers TerrAscend to be Possible Value Trap.
Key valuation signals for STU:TED:
Cash Conversion Cycle: 6.27
GF Value™: €0.85 vs. price of €0.58 (31.5% below fair value)
Industry Position: 95.7% below the Drug Manufacturers median
No single metric tells the full story. See the STU:TED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
38GF Score
Get the complete analysis for STU:TED
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TED has been successfully added to your 
